L
Laguna Bio
Biotech & Life Sciences · Berkeley, United States · Founded 2022
Develops immunotherapies that activate the innate immune system to combat solid tumors MoreLess
Laguna Bio focuses on developing advanced immunotherapy solutions using allogeneic T cells. These cells are expanded ex vivo with IL2, IL15, and zoledronate, which are then paired with bispecific antibodies to harness the immune system's potential for therapeutic purposes. The company addresses safety concerns from previous trials by ensuring that Laguna Listeria cannot grow extracellularly. Laguna Bio operates in the biotechnology sector, targeting healthcare providers and research institutions seeking cutting-edge immunotherapy treatments. The business model likely involves partnerships with medical facilities and research organizations, generating revenue through licensing agreements and collaborative research projects. Keywords: immunotherapy, allogeneic T cells, IL2, IL15, zoledronate, bispecific antibodies, immune response, biotechnology, healthcare, research, licensing.
Talent graph
Laguna Bio's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Laguna Bio has talent and traffic
team presence
Market sentiment
What the market is saying about Laguna Bio
An AI-synthesized read of the highest-engagement posts about Laguna Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Laguna Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.